Cambridge Cognition wins £1.0m schizophrenia clinical trial contract

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m. The revenue from this contract is expected over the next three years. Cambridge Cognition will provide proprietary cognitive assessments (CANTABTM) and specialist, study management services. This contract is a repeat purchase from an existing client that has contracted for several other clinical trials for schizophrenia.

Cognitive impairment is a core feature of schizophrenia, with deficits frequently observed in memory, attention and executive functions. Cambridge Cognition has secured these contracts on the strength of the Company’s reputation for quality service and its cognitive assessments (CANTABTM) capable of measuring the distinct cognitive processes compromised in schizophrenia.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“We are delighted to have formed an enduring partnership with this pharmaceutical company that recognises the potential for our sensitive cognitive assessments to be used in pivotal clinical trials.  This continues to be an exciting area for potential further growth for the Company in the future.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions